The Effect of Carrier Material on the Measured Resistance of Spores - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Effect of Carrier Material on the Measured Resistance of Spores
A biological indicator (BI) measures the effectiveness of the sterilization process to which it is subjected. Factors such as the test organism, the packaging, the culture material, and the test system all influence a BI's resistance. Carrier material is an often-overlooked factor that also influences BI resistance. The authors examine various solid and liquid carriers, describe their properties, and investigate how they influence BI resistance.


Pharmaceutical Technology


A biological indicator (BI) is an "inoculated carrier contained within its primary pack ready for use and producing a defined resistance to the specified sterilization process"(1). The biological component of the BI typically is bacterial endospores.

Defined resistance is a quantitative measure generally expressed in units of time or dose. This value can be the point of BI inactivation (kill). More commonly, resistance is expressed as a D-value. D-value is defined as the time or radiation dose required to inactivate 90% of a population of the test microorganism under stated exposure conditions (1).


Figure 1
Many factors influence the measured resistance of a BI, including the test organism, the carrier material, the primary packaging, the culture medium used for the recovery of stressed spores, and the test system (2–6). The carrier material and packaging often are overlooked as influences on a BI's resistance. All of these items must be controlled to achieve predictable and consistent BI performance.


Figure 2
A major misunderstanding in the industry is that spores have an intrinsic D-value. This assertion is not true if for no other reason than it is impossible to test the resistance of individual spores suspended in space. For testing purposes, the spores are placed onto a surface or suspended in a liquid, and this system becomes the BI. It is the resistance of the system that is measured, not simply the spores. The bacterial spores integrate all known and unknown critical process variables. This article focuses on the effect of carrier materials on the measured resistance of spores on solid and in liquid carrier materials.


Figure 3
A myriad of solid and liquid carrier materials can be used. Solid carriers can be fibrous (e.g., paper, woven polymers, and fiberglass material) or nonfibrous (e.g., stainless steel, plastic, and rubber). Liquid carriers include water, oil, nutrient medium, and pharmaceutical products.


Figure 4
Commercially prepared spore suspensions are used as components in the BI-manufacturing process. Spore suspensions typically are labeled with a D-value. This D-value usually is collected on a carrier of convenience and should be stated on the certificate of analysis (C of A). The spore suspension by itself, however, is not the BI system that the user employs. These suspensions inoculate carriers that then become the BI system. The D-value of the resulting BI system is not specified on the C of A. The C of A, however, provides the user with a means of comparison with previous spore lots.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
The Effect of Carrier Material on the Measured Resistance of Spores
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Radiation Sterilization of Parenterals
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here